Valion Bio, Inc. SEC filings VBIO
Valion Bio, Inc. has 402 filings in SEC EDGAR's recent list, going back to Sep 10, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 20, 2026 | — |
| EFFECT | Filing | Oct 20, 2026 | — |
| DRS | Filing | Oct 5, 2026 | — |
| RW | Registration withdrawal request | Aug 24, 2026 | — |
| EFFECT | Filing | Aug 12, 2026 | — |
| EFFECT | Filing | Apr 15, 2026 | — |
| CORRESP | Letter to the SEC | Apr 13, 2026 | — |
| DRS | Filing | Apr 13, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2026 | — |
| DRS | Filing | Apr 6, 2026 | — |
| EFFECT | Filing | Jan 16, 2026 | — |
| EFFECT | Filing | Jan 16, 2026 | — |
| CORRESP | Letter to the SEC | Jan 14, 2026 | — |
| CORRESP | Letter to the SEC | Jan 14, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2026 | — |
| D | Filing | Dec 29, 2025 | — |
| D | Filing | Dec 29, 2025 | — |
| 1-A-W | Offering statement withdrawal | Sep 17, 2025 | — |
| EFFECT | Filing | Sep 5, 2025 | — |
| CORRESP | Letter to the SEC | Sep 3, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2025 | — |
| EFFECT | Filing | Aug 12, 2025 | — |
| EFFECT | Filing | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2025 | — |
| DRS | Filing | Aug 4, 2025 | — |
| DRSLTR | Filing | Aug 4, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2025 | — |
| EFFECT | Filing | Jul 30, 2025 | — |
| CORRESP | Letter to the SEC | Jul 28, 2025 | — |
| CORRESP | Letter to the SEC | Jul 25, 2025 | — |
| DRS | Filing | Jul 25, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2025 | — |
| CORRESP | Letter to the SEC | Jun 26, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2025 | — |
| CORRESP | Letter to the SEC | Jun 6, 2025 | — |
| UPLOAD | Letter from the SEC | May 21, 2025 | — |
| DRS | Filing | May 15, 2025 | — |
| DRSLTR | Filing | May 15, 2025 | — |
| EFFECT | Filing | May 13, 2025 | — |
| CORRESP | Letter to the SEC | May 9, 2025 | — |
| UPLOAD | Letter from the SEC | May 8, 2025 | — |
| DRS | Filing | May 2, 2025 | — |
| DRSLTR | Filing | May 2, 2025 | — |
| 1-A/A | Filing | Dec 13, 2024 | — |
| 1-A/A | Filing | Nov 7, 2024 | — |
| 1-A/A | Filing | Oct 4, 2024 | — |
| 1-A | Filing | Aug 16, 2024 | — |
| EFFECT | Filing | May 9, 2024 | — |
| CORRESP | Letter to the SEC | May 8, 2024 | — |
| CORRESP | Letter to the SEC | May 8, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2024 | — |
| POS EX | Filing | Feb 9, 2023 | — |
| EFFECT | Filing | Feb 8, 2023 | — |
| EFFECT | Filing | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2023 | — |
| DEL AM | Filing | Feb 2, 2023 | — |
| CORRESP | Letter to the SEC | Jan 25, 2023 | — |
| CORRESP | Letter to the SEC | Jan 24, 2023 | — |
| CORRESP | Letter to the SEC | Jan 18, 2023 | — |
| CORRESP | Letter to the SEC | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 12, 2023 | — |
| CORRESP | Letter to the SEC | Jan 11, 2023 | — |
| CORRESP | Letter to the SEC | Jan 10, 2023 | — |
| CORRESP | Letter to the SEC | Jan 6, 2023 | — |
| CORRESP | Letter to the SEC | Jan 6, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 2, 2022 | — |
| SEC STAFF LETTER | Filing | Nov 10, 2021 | — |
| EFFECT | Filing | Nov 10, 2021 | — |
| CERT | Filing | Nov 10, 2021 | — |
| 8-A12B | Filing | Nov 10, 2021 | — |
| CORRESP | Letter to the SEC | Nov 5, 2021 | — |
| CORRESP | Letter to the SEC | Nov 5, 2021 | — |
| CORRESP | Letter to the SEC | Sep 23, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2021 | — |
| SEC STAFF LETTER | Filing | Sep 15, 2021 | — |
| CORRESP | Letter to the SEC | Sep 9, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2021 | — |
| CORRESP | Letter to the SEC | Aug 12, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2021 | — |
| CORRESP | Letter to the SEC | Aug 3, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 9, 2021 | — |
| DRS/A | Filing | Jul 2, 2021 | — |
| DRSLTR | Filing | Jul 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2021 | — |
| DRS | Filing | May 14, 2021 | — |
| D | Filing | Sep 10, 2019 | — |
Showing 93 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1787740
- Former names
- Tivic Health Systems, Inc. (until Apr 23, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.